# A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

> **NCT03606460** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 141 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab Dose 1
- **DRUG:** Ocrelizumab Dose 2 and Dose 3

## Key facts

- **NCT ID:** NCT03606460
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-05-31
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2020-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606460, "A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03606460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*